Add BrightSurf on Google Email

Living longer with less burden of cancer treatment: new endpoints defined for cancer trials

A new paradigm shift in cancer research defines valid primary study endpoints for oligometastatic disease, focusing on treatment-free time and minimal side effects. The consensus paper establishes two new metrics: STFS (Start or Switch of Systemic Therapy–Free Survival) and pPFS (polymetastatic Progression–Free Survival), which capture...

SourceMedical University of Vienna·JournalThe Lancet Oncology·TypeSystematic review·DateApr 28, 2026

New targeted therapy shows promise against aggressive childhood and adult cancers

A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.

SourceUniversity of British Columbia·JournalCancer Discovery·TypeExperimental study·DateApr 23, 2026

Primary breast tumors already harbor cells with metastatic potential

Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.

SourceUniversidad Miguel Hernandez de Elche·JournalNature Communications·TypeExperimental study·DateApr 20, 2026

Understanding metastasis mechanisms

A research team has identified signalling molecules called Netrins and the corresponding receptor Frazzled/Deleted in Colorectal Cancer that control when individual cells separate from the tumour and migrate. These mechanisms can enable cancer cells to colonize new tissue, a major factor in metastasis.

SourceHeinrich-Heine University Duesseldorf·JournalNature Communications·DateApr 7, 2026

Scalable platform sheds light on how cancer spreads

A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.

SourceRice University·JournalAdvanced Healthcare Materials·TypeExperimental study·DateMar 26, 2026

New discovery on brain metastasis reveals how tumors hijack immune cells to use them to their advantage

A recent study has revealed that brain tumors use a protein called MIF to reprogram immune cells, such as macrophages and microglia, to drive tumor growth. The researchers have identified a drug, ibudilast, which can block this process, slowing metastasis in animal models and fresh patient samples.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCancer Research·TypeExperimental study·DateMar 25, 2026

Mount Sinai study may help cancer patients keep their bladder

Researchers developed a molecular monitoring approach to identify patients with muscle-invasive bladder cancer who can safely preserve their bladder without compromising cancer outcomes. The study found that ultra-sensitive testing of tumor-derived DNA in blood and urine may help predict metastatic risk and identify patients with an ex...

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalProceedings of the National Academy of Sciences·TypeObservational study·DateFeb 19, 2026

Killing cancer cells with RNA therapeutics

In a mouse study, researchers successfully used RNA micelles to shrink metastasized tumors in lungs by delivering chemotherapy drugs and an RNA molecule that blocks cancer survival. The treatment significantly reduced tumor growth and improved outcomes for mice with colorectal cancer lung metastasis.

SourceOhio State University·JournalAdvanced Functional Materials·DateFeb 6, 2026

New England Journal of Medicine publishes phase 3 PATINA trial data demonstrating a significant progression-free survival benefit with palbociclib in metastatic HR+, HER2+ breast cancer

The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.

SourcePrECOG, LLC·JournalNew England Journal of Medicine·DateJan 29, 2026

Blood test may help identify which colon cancer patients benefit from NSAIDs

A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.

SourceAlliance for Clinical Trials in Oncology·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateDec 15, 2025

An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases

A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.

Novel AI technique able to distinguish between progressive brain tumours and radiation necrosis, York University study finds

A new AI-based method can differentiate between tumour progression and radiation necrosis with high accuracy, enabling more accurate identification and treatment of late-stage cancer patients. This discovery could lead to better treatments for brain metastasis patients treated with stereotactic radiosurgery.

SourceYork University·JournalInternational Journal of Radiation Oncology*Biology*Physics·DateDec 8, 2025

Decoding the mechanics of cancer invasion

Biomechanical forces play a crucial role in regulating cancer invasion and metastasis by modulating cell membrane topology, actin cytoskeletal remodeling, and mechanical stress adaptation. The review highlights the importance of three-dimensional tumor models and novel therapies targeting mechanical signaling pathways to inhibit invasion.

SourceCompuscript Ltd·JournalGenes & Diseases·DateNov 7, 2025

Distinguished cancer researcher Stuart S. Martin, PhD, named Chair of the Department of Pharmacology & Physiology at UM School of Medicine

Stuart S. Martin, PhD, has been appointed Chair of the Department of Pharmacology & Physiology at UMSOM, bringing over 20 years of success in advancing basic science research efforts and developing new drug therapies. His groundbreaking discovery of microtentacles on cancer cells promises to lead to new life-extending therapies.

New USC study identifies key genes linked to aggressive prostate cancer in people of African descent

A new USC study identified five genes linked to aggressive prostate cancer in people of African descent, including ATM, BRCA2, CHEK2, HOXB13 and PALB2. The researchers developed a method combining genetic risk scores with family history and specific variant presence for personalized monitoring and treatment strategies.

SourceKeck School of Medicine of USC·JournalEuropean Urology·TypeMeta-analysis·DateNov 5, 2025

Lactate–acetate interaction between tumor-associated macrophages and cancer cells drives hepatocellular carcinoma metastasis

Researchers found that tumor-associated macrophages produce acetate through a metabolic interaction involving lactate and the lipid peroxidation–ALDH2 pathway. This acetate promotes histone H3 acetylation and epithelial-mesenchymal transition in hepatocellular carcinoma cells, enhancing metastasis.

SourceChinese Academy of Sciences Headquarters·JournalNature Metabolism·TypeExperimental study·DateOct 21, 2025

Decoding the secrets of ‘chemo brain’

Researchers suggest chemotherapy drugs may be responsible for 'chemo brain' symptoms, citing reduced lymphatic vessel growth and impaired cognitive function. The study highlights the need to consider long-term neurological side effects of cancer treatment on quality of life.

SourceVirginia Tech·JournalCommunications Biology·TypeExperimental study·DateOct 13, 2025